IRIS
MORGILLO, Floriana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.596
NA - Nord America 3.090
AS - Asia 459
OC - Oceania 9
SA - Sud America 7
AF - Africa 5
Continente sconosciuto - Info sul continente non disponibili 5
Totale 7.171
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.052
IE - Irlanda 1.188
IT - Italia 636
GB - Regno Unito 401
UA - Ucraina 400
DE - Germania 315
FR - Francia 260
CN - Cina 259
SE - Svezia 136
TR - Turchia 111
FI - Finlandia 110
GR - Grecia 98
CA - Canada 37
BE - Belgio 24
VN - Vietnam 24
KR - Corea 22
PK - Pakistan 8
IN - India 7
NL - Olanda 6
NZ - Nuova Zelanda 6
EU - Europa 5
SG - Singapore 5
TW - Taiwan 5
CH - Svizzera 4
CO - Colombia 4
IR - Iran 4
MK - Macedonia 4
PH - Filippine 4
AU - Australia 3
ES - Italia 3
MA - Marocco 3
HK - Hong Kong 2
HU - Ungheria 2
IL - Israele 2
PL - Polonia 2
RS - Serbia 2
AT - Austria 1
BR - Brasile 1
CL - Cile 1
EG - Egitto 1
IQ - Iraq 1
JP - Giappone 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MY - Malesia 1
NO - Norvegia 1
PA - Panama 1
PE - Perù 1
PS - Palestinian Territory 1
RO - Romania 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 7.171
Salva come PNG Salva come JPEG
Città #
Dublin 1.180
Chandler 662
Jacksonville 630
Princeton 165
Bremen 163
Medford 129
Ann Arbor 128
Roxbury 126
New York 122
Caserta 117
Wilmington 87
Beijing 81
Naples 78
Nanjing 54
Boardman 53
San Mateo 46
Cambridge 45
Woodbridge 45
Des Moines 38
Ashburn 34
Napoli 34
Elora 28
Brussels 24
Dong Ket 24
Houston 24
Jinan 19
Mountain View 18
Nanchang 16
Aiello Del Sabato 14
Düsseldorf 13
Norwalk 12
Lappeenranta 10
Tianjin 10
Auburn Hills 9
Helsinki 9
Los Angeles 9
Rome 9
Cava Dei Tirreni 7
Lanzhou 7
Venice 7
Hebei 6
Kunming 6
London 6
Munich 6
Shanghai 6
Shenyang 6
Somma Vesuviana 6
Zhengzhou 6
Acerra 5
Amsterdam 5
Changchun 5
Fairfield 5
Hangzhou 5
Milan 5
Redwood City 5
Taiyuan 5
Giugliano in Campania 4
Ningbo 4
Ottawa 4
Padova 4
Taizhou 4
Zurich 4
Andover 3
Aversa 3
Changsha 3
Ercolano 3
Haikou 3
Hanover 3
Marigliano 3
Orange 3
Pagani 3
Redmond 3
Singapore 3
Toronto 3
Anantapur 2
Athens 2
Avellino 2
Bagnoli Irpino 2
Barcelona 2
Bat Hefer 2
Battipaglia 2
Bergamo 2
Bogotá 2
Caivano 2
Casoria 2
Castellammare Di Stabia 2
Cinquevie 2
Elmas 2
Falls Church 2
Forino 2
Guangzhou 2
Hong Kong 2
Jiaxing 2
L'aquila 2
Lustra 2
Menlo Park 2
Molinella 2
Mugnano Di Napoli 2
Nola 2
Paris 2
Totale 4.486
Salva come PNG Salva come JPEG
Nome #
ONCOLOGIA MEDICA 143
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 91
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 85
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 83
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: A propensity score-matched analysis 83
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 82
Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma—a pilot study. Curr Oncol 21, 3, june 2014 125-133 80
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 78
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 78
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 74
Control of post-thoracotomy pain by transcutaneous electrical nerve stimulation: effect on serum cytokine levels, visual analogue scale, pulmonary function and medication(dagger) 74
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 71
A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. 70
Chronic inflammation and oxidative stress in human carcinogenesis 70
Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer 70
TRASTUZUMAB RESISTANCE IN BREAST CANCER 70
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 68
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 68
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 68
Farmacogenomica e cancro colorettale 66
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics 65
First-Line Erlotinib Followed by Second-Line Cisplatin- Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial 62
Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. 62
Phosphatidylinositol 3-kinase (PI3Ka)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells 62
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 61
AXL is an oncotarget in human colorectal cancer 61
Cisplatin in addition to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC): efficacy results of a joint analysis of the multicentre, randomized phase 3 MILES-3 and MILES-4 studies 61
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 60
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 60
Treatment of Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. 58
The value of matrix metalloproteinase-9 and vascular endothelial growth factor receptor 1 pathway in diagnosing indeterminate pleural effusion. 58
Adequacy of Cytologic Samples by Ultrasound-Guided Percutaneous Transthoracic Fine-Needle Aspiration Cytology of Peripheral Pulmonary Nodules for Morphologic Diagnosis and Molecular Evaluations: Comparison With Computed Tomography-Guided Percutaneous Transthoracic Fine-Needle Aspiration Cytology 58
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 57
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 57
Combination of anti-EGFR drugs and other molecular targeted agents as anti-cancer strategy 57
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 57
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 56
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 56
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 56
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 56
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib 55
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials 55
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracyclina-induced cardiotoxicity (review) 55
Post- operative xelox and chemoradiation in stage III-IV radically resected gastric cancer patients: preliminary results of a pilot study. 55
Conversion chemotherapy followed by epatic resection in colorectal cancer with initially unresectable liver-limited metastases 54
Complete response to preoperative chemoradiation and survival in esophageal cancer : a pooled analysis of three singe-institution phase II trials. 54
Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab? 53
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: Case report and translational study 53
Trimodality treatment in early-stage malignant pleural mesothelioma. Preliminary results of a multicenter phase II trial 52
Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. 51
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer 51
A trimodality, four-step treatment including chemotherapy, pleurectomy/decortication and radiotherapy in early-stage malignant pleural mesothelioma: A single-institution retrospective case series study 51
Serum vascular endothelial growth factor (VEGF)levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer 50
Lonafarnib in cancer therapy 50
Tumori neuroendocrini (NETs) 50
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study 50
MET ACTIVATION BY AUTOCRINE LOOP RESCUES COLON CANCER CELLS FROM SENSITIVITY TO EGFR INHIBITION 50
Targeting EGFR in Pancreatic Cancer Treatment. 50
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs 50
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis 49
PET-TC BODY CON FDG IN ONCOLOGIA 49
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 49
Preoperative chemo-radiotherapy for carcinoma of the esophagus 48
Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment 48
Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis 48
Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival 48
Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy 47
Erlotinib in cancer treatment 47
It is finally time for adjuvant therapy in melanoma 47
Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota 47
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells 46
Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: A phase II study 46
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 46
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 46
MEK inhibitor as a single agent and in combination with everolimus or sorafenib in a panel of colorectal cancer cell lines: implication for multitargeted approach 45
Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. 45
Mechanisms of resistance to EGFR-targeted drugs: lung cancer 45
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials 45
Metformin in lung cancer: rationale for a combination therapy 44
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 44
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines 44
OPTIMIZING THERAPEUTIC COMBINATIONS OF A SELECTIVE MEK 1/2 INHIBITOR (PIMASERTIB) WITH PI3K/ MTOR INHIBITORS OR WITH MULTI-TARGETED KINASE INHIBITORS IN PIMASERTIB-RESISTANT HUMAN LUNG AND COLORECTAL CANCER CELLS 44
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. 44
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 44
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 44
Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer 43
Il Carcinoma della vescica 43
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 43
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer 42
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 42
BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. 42
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 42
Resistance mechanisms of tumour cells to EGFR inhibitors 41
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 41
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 40
Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold! 40
Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells 39
Il Carcinoma Gastrico 39
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 39
Mechanisms of intrinsic and acquired resistance to EGFR inhibotors 38
Totale 5.554
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.170
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.170
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019108 0 0 0 0 0 0 0 0 0 0 89 19
2019/2020943 162 125 38 21 108 21 163 75 93 53 68 16
2020/20211.038 86 18 113 59 165 12 140 99 23 133 127 63
2021/20221.191 56 17 25 28 376 17 45 45 49 101 108 324
2022/20232.507 254 65 39 245 312 203 11 146 1.118 19 49 46
2023/2024719 82 34 43 55 292 132 18 26 16 18 3 0
Totale 7.546